COMMUNIQUÉS West-GlobeNewswire

Virbac : Déclaration d'actions et de droits de vote au 31 Mai 2017

02/06/2017 - 13:46

DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]

Virbac : Declaration of the number of shares and voting rights as of May 2017, 31.

02/06/2017 - 13:46

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

XBiotech présente des résultats de phase III pour son traitement par anticorps du cancer colorectal lors de la réunion ASCO de 2017

02/06/2017 - 13:45

Les données montrent une moindre progression de la maladie et une survie améliorée pour les patients atteignant le critère d'évaluation principal AUSTIN, Texas, le 1 er juin 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ [...]

Nexstim Plc Agrees on Extension of Tekes R&D Loan Repayments

02/06/2017 - 13:30

Company announcement, Helsinki, 2 June 2017 at 2:30 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]

Crown Bioscience affiche une maîtrise approfondie des modèles PDX et une expertise émergente en immuno-oncologie

02/06/2017 - 10:39

Avancées scientifiques en immuno-oncologie post-AACR SANTA CLARA, Californie, 2017-06-02 (GLOBE NEWSWIRE) - Crown Bioscience , une filiale en propriété exclusive de Crown Bioscience International (TWSE : code boursier [...]

Orion Diagnostica's co-operation negotiations in Oulu completed

02/06/2017 - 10:06

ORION CORPORATION PRESS RELEASE 2 JUNE 2017 at 11.06 a.m. EEST Orion Diagnostica's co-operation negotiations in Oulu completed The co-operation negotiations which were initiated in April in Orion Diagnostica Oy, a [...]

Zealand to present at two international healthcare investor conferences in June 2017

02/06/2017 - 09:26

Press Release - No. 4 / 2017 Zealand to present at two international healthcare investor conferences in June 2017 Copenhagen, June 2, 201 7 - Zealand announces that its President and CEO, Britt Meelby Jensen, and [...]

Tecan appoints Erik Norström Head of Corporate Development

02/06/2017 - 07:25

Männedorf, Switzerland, June 2, 2017 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that Erik Norström has been appointed Head of Corporate Development and a member of the Management Board. He will assume [...]

Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

02/06/2017 - 07:15

At a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared to 16.0 months for [...]

Basilea names new member of its Extended Management Committee

02/06/2017 - 07:15

Basel, Switzerland, June 2, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of August 1, 2017, Damian Heller will assume the role of General Counsel & Corporate Secretary and join the Extended [...]

Biocartis Group NV: Disclosure of a transparency notification

02/06/2017 - 07:00

PRESS RELEASE: REGULATED INFORMATION 2 June 2017, 07:00 CEST Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, Belgium, 2 [...]

Merus fera une présentation à la Jefferies 2017 Global Healthcare Conference

02/06/2017 - 01:27

UTRECHT, Pays-Bas, le 1 er juin 2017 - Merus N.V. (Nasdaq : MRUS), une entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques, a annoncé aujourd'hui que [...]

Mice in Space: Taconic Mice Included on Launch to International Space Station

01/06/2017 - 20:54

HUDSON, N.Y., June 01, 2017 (GLOBE NEWSWIRE) -- When the SpaceX Dragon spacecraft launches today bound for the International Space Station, they will be joined by 40 special mice, bred specifically for this mission by [...]

NICOX : Nombre de droits de vote au 31 mai 2017

01/06/2017 - 17:40

Nicox SA Société anonyme au capital de 25 070 977 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 1 juin 2017, PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS [...]

NICOX : Number of voting rights as of May 31, 2017

01/06/2017 - 17:40

Nicox SA Société anonyme with a registered capital of € 25,070,977 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On June 1, 2017, MONTHLY PUBLICATION OF THE [...]

Bavarian Nordic to Present at Jefferies 2017 Healthcare Conference in New York

01/06/2017 - 17:30

COPENHAGEN, Denmark - June 1, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at the Jefferies 2017 [...]

Virbac : communiqué de mise à disposition des documents préparatoires à l'AG

01/06/2017 - 11:06

VIRBAC ________________ Le 30 mai 2017 communique precisant les modalités de mise a disposition ou de consultation des documents preparatoires a l'assemblee generale Les actionnaires de VIRBAC sont convoqués en [...]

Nicox : Communiqué sur le bilan de fin du contrat de liquidité conclu avec Gilbert Dupont

01/06/2017 - 09:52

Communiqué de presse Nicox : Communiqué sur le bilan de fin du contrat de liquidité conclu avec Gilbert Dupont 1 er juin 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), [...]

GENFIT : issue positive du DSMB suite à la revue planifiée à 1 an des données de tolérance et de sécurité d'emploi d'elafibranor, dans l'étude clinique de Phase 3 RESOLVE-IT

01/06/2017 - 08:30

GENFIT : issue positive du DSMB suite à la revue planifiée à 1 an des données de tolérance et de sécurité d'emploi d'elafibranor, dans l'étude clinique de Phase 3 RESOLVE-IT Les données de tolérance et de sécurité d' [...]